More Articles

Biosimilar drug packaging does not meet EU guidelines on readability Biosimilars/Research | Posted 19/04/2019

Analysis of 35 biosimilar medicines licensed by the European Medicines Agency (EMA) finds packaging to be more complex than recommended. None of the packaging leaflets analysed were found to be ‘ea...

Rituximab biosimilar Truxima approved in Canada Biosimilars/News | Posted 19/04/2019

Teva Canada Innovation, a subsidiary of Teva Pharmaceutical Industries, announced on 10 April 2019 that Health Canada had approved its rituximab biosimilar Truxima. This marks the first rituximab b...

WHO Global Benchmarking Tool Revision VI includes ‘Listed Authorities’ Reports | Posted 19/04/2019

To help countries to build effective regulatory systems, the latest World Health Organization (WHO) Global Benchmarking Tool includes a shift towards ‘WHO-listed authorities’ (WLAs), replacing the...

Eli Lilly to introduce half-price authorized insulin biosimilar in US Biosimilars/General | Posted 19/04/2019

With high drug prices increasingly coming into the spotlight, Eli Lilly has announced that it will introduce a lower-priced authorized biosimilar version of its diabetes treatment Humalog (insulin...

Online consultation on biological drug naming in Canada Policies & Legislation | Posted 19/04/2019

Health Canada and the Institute for Safe Medication Practices Canada conducted an online consultation on the naming of biological drugs in 2018.

Celltrion has renewed success with leukaemia biosimilar Truxima and expands markets in Europe and Latin America Pharma News | Posted 19/04/2019

In recent months, South Korean biosimilars firm Celltrion has announced a series of successes, including winning a patent case against Samsung Biogen and expansions in the European and Latin Americ...

Economic considerations for biosimilars in the US Biosimilars/Research | Posted 19/04/2019

Smeeding and colleagues explore cost considerations related to biosimilars in the US, and present a broad perspective on value beyond price reduction in a recent review. 

Stada launches generic Exforge following patent revocation Generics/News | Posted 19/04/2019

German generics producer Stada Arzneimittel announced on 20 March 2019 that it is set to launch a generic version of the antihypertensive Exforge (amlodipine/valsartan combination), following the r...